2010 – 2009 and 2010 have seen some of the biggest mergers, acquisitions and licensing activities the pharmaceutical industry has undergone in a very long time. In light of dwindling pipeline products, impending patent expirations for several blockbuster drugs, tight budgets and cost cuts due to the recession, several major pharmaceutical companies are looking at licensing promising drug compounds from biotech or other pharmaceutical companies to remain competitive in the market.
In response to these developments, Frost & Sullivan has organised a complimentary web conference, entitled Pharma-Biotech Licensing Deals – Stopgap Option or Way of the Future?, to take place on Thursday, 2nd September 2010, at 2 p.m. BST. Research Analyst, Ms. Swetha Shantikumar, will give an analysis of licensing trends by deal value, geographic region, therapeutic area and stage of drug development.
“Option-based deals are a leading choice for the large pharmas to hedge financial risk in tough economic times, while exploiting opportunities to license promising drug candidates in early stages of clinical development,” observes Shantikumar. “This will typically yield better return-on-investments in a less competitive environment”.
For more information, visit www.frost.com
In response to these developments, Frost & Sullivan has organised a complimentary web conference, entitled Pharma-Biotech Licensing Deals – Stopgap Option or Way of the Future?, to take place on Thursday, 2nd September 2010, at 2 p.m. BST. Research Analyst, Ms. Swetha Shantikumar, will give an analysis of licensing trends by deal value, geographic region, therapeutic area and stage of drug development.
“Option-based deals are a leading choice for the large pharmas to hedge financial risk in tough economic times, while exploiting opportunities to license promising drug candidates in early stages of clinical development,” observes Shantikumar. “This will typically yield better return-on-investments in a less competitive environment”.
For more information, visit www.frost.com
